Background illustration for clinical trials search

Paid Clinical Trials Billings

Discover 125 paid clinical trials in Billings, Montana. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.

Filter

Filter results

Results: 125

Active & Responsive

A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)

for

Prostate Cancer, Prostatic Neoplasms

Location: Billings MT, Aurora CO, Seattle WA, Portland OR,

Sponsor: Merck Sharp & Dohme LLC

Sex: Male

Age: 18+

Code: NCT06925737

Phase3, Recruiting

Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

for

Anatomic Stage II Breast Cancer AJCC v8,

Location: Fort Collins CO, Boise ID, Loveland CO,

Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT06058377

Phase3, Recruiting

Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer

for

Fallopian Tube Endometrioid Adenocarcinoma,

Location: Billings MT, Cody WY, Bozeman MT, Great Falls MT,

Sponsor: NRG Oncology

Sex: All

Age: 18+

Code: NCT06580314

Phase3, Recruiting

A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)

for

Relapsing Multiple Sclerosis, Multiple Sclerosis

Location: Billings MT, Ogden UT, Salt Lake City UT, Smith UT,

Sponsor: TG Therapeutics, Inc.

Sex: All

Age: 18+

Code: NCT06433752

Recruiting

Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)

for

Myelodysplastic Syndrome

Location: Billings MT, Bozeman MT, Great Falls MT, Anaconda MT,

Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT06577441

Phase2, Recruiting

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

for

Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8,

Location: Billings MT, Bozeman MT, Great Falls MT, Anaconda MT,

Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT06498635

Phase3, Recruiting

Family Communications After Genetic Testing

for

Colon Adenocarcinoma, Colorectal Adenocarcinoma,

Location: Billings MT, Cody WY, Bozeman MT, Great Falls MT,

Sponsor: Alliance for Clinical Trials in Oncology

Sex: All

Age: 18+

Code: NCT07143487

Recruiting

Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial

for

Metastatic Castration-Resistant Prostate Carcinoma,

Location: Billings MT, Bozeman MT, Great Falls MT, Missoula MT,

Sponsor: Alliance for Clinical Trials in Oncology

Sex: Male

Age: 18+

Code: NCT07200830

Phase3, Recruiting

Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial

for

Anatomic Stage II Breast Cancer AJCC v8,

Location: Billings MT, Bozeman MT, Great Falls MT, Missoula MT,

Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT07391774

Phase3, Recruiting

Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

for

B Acute Lymphoblastic Leukemia

Location: Billings MT, Bozeman MT, Great Falls MT, Anaconda MT,

Sponsor: Alliance for Clinical Trials in Oncology

Sex: All

Age: 18 - 39

Code: NCT03150693

Phase3, Recruiting

Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations

for

Locally Advanced Pancreatic Adenocarcinoma,

Location: Billings MT, Cody WY, Bozeman MT, Great Falls MT,

Sponsor: SWOG Cancer Research Network

Sex: All

Age: 18+

Code: NCT06998940

Phase3, Recruiting

Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)

for

Acute Myeloid Leukemia

Location: Billings MT, Bozeman MT, Great Falls MT, Anaconda MT,

Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT06672146

Phase2, Recruiting

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study

for

Muscle Invasive Bladder Urothelial Carcinoma,

Location: Billings MT, Bozeman MT, Great Falls MT, Havre MT,

Sponsor: NRG Oncology

Sex: All

Age: 18+

Code: NCT07097142

Phase3, Recruiting

A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer

for

Locally Advanced Urothelial Carcinoma,

Location: Billings MT, Bozeman MT, Great Falls MT, Anaconda MT,

Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT06524544

Phase3, Recruiting

ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab

for

Anatomic Stage I Breast Cancer AJCC v8,

Location: Billings MT, Bozeman MT, Great Falls MT, Anaconda MT,

Sponsor: Alliance for Clinical Trials in Oncology

Sex: All

Age: 18+

Code: NCT06876714

Phase3, Recruiting

Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial

for

Castration-Sensitive Prostate Carcinoma,

Location: Billings MT, Bozeman MT, Great Falls MT, Anaconda MT,

Sponsor: Alliance for Clinical Trials in Oncology

Sex: Male

Age: 18+

Code: NCT06931340

Phase3, Recruiting

Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer

for

Locally Advanced Cervical Adenocarcinoma,

Location: Billings MT, Cheyenne WY, Farmington UT,

Sponsor: National Cancer Institute (NCI)

Sex: Female

Age: 18+

Code: NCT07061977

Phase3, Recruiting

Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study

for

Extensive Stage Lung Small Cell Carcinoma,

Location: Billings MT, Bozeman MT, Great Falls MT, Anaconda MT,

Sponsor: SWOG Cancer Research Network

Sex: All

Age: 18+

Code: NCT06769126

Phase2, Recruiting

Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial

for

Lung Non-Small Cell Carcinoma

Location: Billings MT, Bozeman MT, Great Falls MT, Missoula MT,

Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT07388524

Phase3, Recruiting

Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL

for

Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia

Location: Billings MT, Bozeman MT, Great Falls MT, Anaconda MT,

Sponsor: Alliance for Clinical Trials in Oncology

Sex: All

Age: 65+

Code: NCT07321652

Phase3, Recruiting

Paid Clinical Trials Billings

Filter results

A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)

Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer

A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)

Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)

Interested in new trials?

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

Family Communications After Genetic Testing

Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial

Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial

Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations

Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study

A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer

ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab

Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial

Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer

Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study

Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial

Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL